Oxendine v. Merck & Co.

236 F. Supp. 2d 517
CourtDistrict Court, D. Maryland
DecidedDecember 18, 2002
DocketNo. CIV.AMD 02-2906, CIV.AMD 02-2908 to CIV.AMD 02-2910, CIV.AMD 02-3248 to CIV.AMD 02-3253, CIV.AMD 02-3258 to CIV.AMD 02-3272, CIV.AMD 02-3279 to CIV.AMD 02-3288, CIV.AMD 02-3290, CIV.AMD 02-3292, CIV.AMD 02-3293, CIV.AMD 02-3295 to CIV.AMD 02-3298, CIV.AMD 02-3817 to CIV.AMD 02-3822, CIV. AMD 02-3261
StatusPublished
Cited by11 cases

This text of 236 F. Supp. 2d 517 (Oxendine v. Merck & Co.) is published on Counsel Stack Legal Research, covering District Court, D. Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Oxendine v. Merck & Co., 236 F. Supp. 2d 517 (D. Md. 2002).

Opinion

MEMORANDUM

DAVIS, District Judge.

I. INTRODUCTION

As the gravamen of their principal claims in these cases, plaintiffs allege that their minor children suffered an increased risk of developmental harms and specifically, autism, which were proximately caused by the administration of various childhood vaccines containing the preservative thim-erosal, the composition of which contains mercury. It has recently been reported that in the last two years more than 4000 such lawsuits have been filed in state and federal courts. See Paul Hamper, Plaintiff Parents Rip Shield for Vaccine Makers; Suits Claiming Autism Link Face Threat from Provision in Homeland Security Law, St. Louis Post-Dispatch, Dec. 10, 2002, at 1A. The 49 cases covered by this memorandum and order comprise a small part of those thousands of cases.

The multifaceted legal and procedural issues surrounding the so-called thimerosal litigation have been examined at length in several thoughtful and well-reasoned, though admittedly not wholly consistent, opinions issued by numerous federal district courts and the Court of Federal Claims and need not be repeated here. See Case v. Merck & Co., No: 02-1779, 2002 WL 31478219 (E.D.La. Nov.5, 2002); Wax v. Aventis Pasteur Inc., No. 2-2018, — F.Supp.2d -, 2002 WL 31444878 (E.D.N.Y. Oct. 30, 2002); Bertrand v. Aventis Pasteur Laboratories, Inc., 226 F.Supp.2d 1206 (D.Ariz.2002); Liu v. Aventis Pasteur, Inc., 219 F.Supp.2d 762 (W.D.Tex.2002); Cheskiewicz by Cheskiewicz v. Aventis Pasteur, Inc., No. 02-3583, 2002 WL 1880524 (E.D.Pa. Aug.15, 2002); King v. Aventis Pasteur, Inc., 210 F.Supp.2d 1201 (D.Or.2002); Owens v. American Home Products Corp., 203 F.Supp.2d 748 (S.D.Tex.2002); O’Connell v. American Home Products Corp., No. G-02-184, 2002 WL 31455729 (S.D.Tex. May 7, 2002); Leroy v. Secretary of Dept. of Health and Human Services, No. 02-392V, 2002 WL 31730680 (Fed.Cl. Oct 11, 2002); Lemire v. Secretary of Dept. of Health and Human Services, 2002 WL 31441209 (Fed.Cl. Sep. 25, 2002); Vessels v. Secretary of Dept. of Health and Human Services, No. 02-182V, 2002 WL 31441210 (Sep. 25, 2002); In re Claims for Vaccine Injuries Resulting in Autism Spectrum Disorder or a Similar Neurodevelopmental Disorder, 2002 WL 31696785 (Fed.Cl. Jul 3, 2002).

The Maryland round of thimerosal litigation arrived in the summer and fall of this year when the same law firm filed 50 cases in the Circuit Court for Baltimore City. All of these cases were timely removed to this court on the basis of diversity of citizenship. Subsequently, plaintiffs timely moved to remand each of the cases. For the reasons set forth herein, ‘ I shall grant the motions for remand.

II. THE FOUR GROUPS OF CASES

The 49 cases covered by this opinion may be usefully considered as falling into [522]*522four separate groupings, although the boundaries between the groups are not as neat as one would hope. In this section, I shall summarize the undisputed facts underlying the issues presented by the motions for remand in all of the cases, and then discuss the procedural history of each of the separate groupings.

In every case, plaintiffs generally allege that their children suffered injuries resulting from repeated exposure to thimerosal, a mercury containing preservative added to some vaccines and other pharmaceutical products. Plaintiffs further allege that their children’s injuries were exacerbated by their exposure to toxic mercury emitted by coal-burning power plants owned and operated by Baltimore Gas & Electric Co. (“BGE”) and Constellation Energy Group (“CEG”), each of which is a citizen of Maryland for purposes of diversity jurisdiction. Plaintiffs seek substantial relief, including damages, on numerous statutory and common law theories. No federal claim is asserted in any case. With only one or two variations, the identity of the approximately 14 defendants in each case is the same.

A. Group One (five cases)

Complete diversity exists in the Group One cases, where all the plaintiffs in this group are citizens of Virginia and none of the defendants is a citizen of Virginia. Defendant Aventis Pasteur, Inc., which for diversity purposes is not a citizen of either Maryland or Virginia, removed the first four cases listed in the caption to this opinion, on September 3, 2002.1 Plaintiffs filed these four cases on or about July 31, 2002 in the Circuit Court for Baltimore City. Apparently, Aventis learned of the filing of the thimerosal suits well before it (or any other defendant) had been served with process.2 In addition, the Group One cases include Good, No. AMD 02-3287. Unlike the first four cases, defendant Smithkline Beecham Corporation removed the Good case on October 4, 2002, after defendants had been served with process.

All the defendants have consented to removal. Although complete diversity exists in these cases, because plaintiffs originally joined two Maryland corporations as defendants, and later joined two more Maryland corporations after defendants’ scramble to remove before plaintiffs served many defendants with process, the removal statute may, and I conclude does, bar removal.

Plaintiffs timely filed motions to remand on September 27, 2002, in the first four cases, and on October 15, 2002, in the Good case. Defendants argue that removal was appropriate in all five cases because the Maryland defendants are fraudulently joined in an effort to defeat diversity jurisdiction. Defendants also argue that the first four cases in Group One were properly removed because plaintiffs had not served the resident defendants at the time of their removal.

B. Group Two (36 cases)

Group Two consists of 36 cases and complete diversity is lacking in each. All [523]*523of the plaintiffs in these cases are citizens of Maryland, and the presence of four Maryland defendants, including BGE and CEG, defeats diversity. After plaintiffs’ served these, and several other, defendants, Wyeth Pharmaceuticals, Inc., on October, 4, 2002, removed some of the cases in this group; defendant Merck and Co., Inc., removed some of the cases; defendant Baxter Pharmaceuticals, Inc., removed some of the cases; and Aventis Pasteur, Inc., removed some of the cases. Apparently, all defendants timely consented to the respective removals. Plaintiffs moved to remand these cases on October 15, 2002. In opposing plaintiffs’ timely motions to remand, defendants argue that the removals were appropriate based on the “fraudulent joinder” doctrine and that, accordingly, the Maryland defendants should be disregarded in determining the existence of subject matter jurisdiction.

C. Group Three (one case)

Group Three consists of one case, Bell, No. AMD 02-3279, in which plaintiffs Robert and Randi Bell are citizens of Pennsylvania. Aside from plaintiffs’ citizenship, this case presents the same procedural history as the cases in Group Two. Defendant Eh Lilly and Company removed the Bell case on October 4, 2002, and plaintiffs moved to remand the same on October 15, 2002. In Bell,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Sutton v. Adams
D. South Carolina, 2023
John Doe 305 v. Richter, Jr.
D. South Carolina, 2023
Kickin Chicken LLC v. TFD Inc
D. South Carolina, 2022
Billie v. Vallance
D. Maryland, 2021
Pratt v. Alaska Airlines Inc
W.D. Washington, 2021
Shadie Ex Rel. Shadie v. Aventis Pasteur, Inc.
254 F. Supp. 2d 509 (M.D. Pennsylvania, 2003)
Oxendine v. Merck and Co., Inc.
236 F. Supp. 2d 517 (D. Maryland, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
236 F. Supp. 2d 517, Counsel Stack Legal Research, https://law.counselstack.com/opinion/oxendine-v-merck-co-mdd-2002.